JY
KROS icon

Jeff Yass’s Keros Therapeutics KROS Stock Holding History

Jeff Yass’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-48,400
Closed -$534K – 14017
2026
Q1 		$534K Buy
+48,400
New +$747K ﹤0.01% 9489
2025
Q4 		– Sell
-189,200
Closed -$2.99M – 13029
2025
Q3 		$2.99M Sell
189,200
-569,300
-75% -$8.41M ﹤0.01% 4982
2025
Q2 		$10.1M Buy
758,500
+285,400
+60% +$3.85M ﹤0.01% 2815
2025
Q1 		$4.82M Buy
473,100
+427,000
+926% +$4.96M ﹤0.01% 3721
2024
Q4 		$730K Buy
46,100
+42,400
+1,146% +$2.2M ﹤0.01% 7727
2024
Q3 		$215K Buy
+3,700
New +$183K ﹤0.01% 10329
2024
Q2 		– Sell
-5,900
Closed -$391K – 12701
2024
Q1 		$391K Buy
+5,900
New +$350K ﹤0.01% 9084

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jeff Yass's KROS Position: Q2 2026 in Review

Jeff Yass increased its Keros Therapeutics (KROS) stake by 87% in Q2 2026, buying an estimated $109K and bringing the position to 21,043 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #11691.

Jeff Yass first reported a position in KROS in Q4 2020 and has held it in 20 quarters since. The position peaked at $3.43M in Q3 2025. 131 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Jeff Yass held 21,043 shares of Keros Therapeutics worth $225K as of Q2 2026.
  • Jeff Yass bought 9,801 Keros Therapeutics shares in Q2 2026, an estimated $109K.
  • Keros Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11691 holding.
  • Jeff Yass first reported a position in Keros Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • Jeff Yass's Keros Therapeutics position peaked at $3.43M in Q3 2025.
  • 131 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.